PMGC unit signs Licensing Agreement Amendment with MOA Life Plus

PMGC (ELAB) Holdings’ wholly owned subsidiary, NorthStrive Biosciences, announced a third amendment to its existing License Agreement with MOA Life Plus Co., a Korean biotechnology company Northstrive Biosciences holds for EL-32 and EL-22. The Amendment updates the timing and key development milestones for EL-32 and EL-22 human clinical development programs, aligning the schedule with the parties’ research and development and regulatory expectations. Northstrive Biosciences believes the Amendment reinforces the company’s commitment to disciplined development planning and the continued progression of its human health portfolio.